Hyperlipidaemia News

  • 30 August 2020
    Results from the HAUSER-RCT trial show that treatment with evolocumab safely reduced LDL cholesterol by almost 40% against a background of statin and diet, in children and adolescents with heterozygous familial hypercholesterolaemia. Heterozygous familial hypercholesterolaemia (FH) is one of the most common metabolic disorders, affecting about one...
  • 30 August 2020
    HAUSER RCT showed that treatment with the PCSK9 monoclonal antibody evolocumab, against a background of usual care (statin, with ezetimibe in 12-15% of patients), was effective and safe in children and adolescents with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) (1). The question is: Does this therapy have a role...
  • 30 August 2020
    PCSK9 Forum Editor Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) comments on the findings of the HASUER-RCT study and potential implications for patient care. HAUSER-RCT is an important study for the care of children and adolescents with familial hypercholesterolaemia (FH). The study evaluated the PCSK9...
  • 29 July 2020
    People living with human immunodeficiency virus (HIV) infection are at increased risk of atherosclerotic cardiovascular disease (ASCVD) compared with those without this infection despite more extensive use of antiretroviral therapy and increased use of statin therapy (1). This increased risk relates to the presence of impaired coronary endothelial...
  • 28 July 2020
    Alirocumab   Trial Study in Participants With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH) ClinicalTrials.gov Identifier: NCT03156621 Aim To assess low-density lipoprotein cholesterol (LDL-C) reduction with alirocumab in adult patients with HoFH. Study design Randomised, double-blind, placebo-controlled, parallel-group,...
  • 27 July 2020
    According to this report, about half of all patients hospitalised for an acute coronary syndrome (ACS) would be eligible for treatment with a PCSK9 inhibitor, based on the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) dyslipidaemia guidelines. This contrasts with about one in seven based on the 2018 American...
  • 27 July 2020
    A new analysis from the FOURIER study suggests that lowering LDL cholesterol with evolocumab led to benefit across various myocardial infarction (MI) subtypes linked to plaque rupture. The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) study previously demonstrated significant reduction in...
  • 27 July 2020
    Data from an experimental model provide support for clinically relevant effects of PCSK9 inhibitors in reducing postprandial lipaemia, especially in patients with type 2 diabetes mellitus. Elevated postprandial lipaemia is an independent risk factor for atherosclerotic cardiovascular disease (1). In previous studies using a mouse model, PCSK9...
  • 27 July 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Chris Packard  The post Remnant lipoproteins and impact of PCSK9 inhibition appeared first on PCSK9 Forum.
  • 27 July 2020
    Professor Chris Packard (Institute of Cardiovascular and Medical Sciences, Glasgow University, UK) discusses how PCSK9 inhibition might affect remnant particles.  The case for the causality of LDL cholesterol in atherosclerotic cardiovascular disease (ASCVD) is indisputable (1). Consequently, attention has now focused on the role of triglyceride-...
  • 13 July 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Dr Charles Paulding and Amy Damask  The post Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES appeared first on PCSK9 Forum.
  • 13 July 2020
    Reports from the 12th Closed Virtual Expert Meeting of the PCSK9 Education and Research Forum Professor Anne Tybjaerg-Hansen  The post Genetic risk scores: How much do they add? appeared first on PCSK9 Forum.
  • 08 July 2020
    Reports from the 12th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Francois Mach  The post What’s new in very high-risk patients? appeared first on PCSK9 Forum.
  • 30 June 2020
    Attaining lower LDL cholesterol levels in patients with ischaemic stroke of atherosclerotic origin led to greater regression of carotid atherosclerosis compared with those at higher LDL cholesterol levels. The results lend further support for lower LDL cholesterol levels in stroke patients. With uncertainty around specific LDL cholesterol targets...
  • 30 June 2020
    Evolocumab outperformed ezetimibe in terms of efficacy and achievement of lipid goals, according to this latest pooled analysis of Phase 3 studies in the PROFICIO development program for evolocumab. High-intensity statin treatment is the cornerstone of lipid lowering therapy for patients at high- and very high-risk of atherosclerotic...
  • 24 June 2020
    Reports from the 12th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Ulf Landmesser  The post Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes appeared first on PCSK9 Forum.
  • 22 June 2020
    Trial A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-5) ClinicalTrials.gov Identifier: NCT03851705 Aim To evaluate the safety, tolerability, and efficacy of inclisiran in subjects with homozygous familial hypercholesterolemia (HoFH) Study Design Multicentre Phase III study conducted in two...
  • 22 June 2020
    First reported at the 87th European Atherosclerosis Society Congress in Maastricht, the Netherlands, the ORION-2 study has now been published. ORION-2 was an open-label, proof-of-concept study that investigated inclisiran, an siRNA therapeutic targeting PCSK9, in four patients with a clinical or genetic diagnosis of homozygous familial...
  • 22 June 2020
    Professor Pierre Amarenco, Bichat Hospital, University of Paris, Paris, France, makes the case for reconsideration of LDL cholesterol targets to prevent stroke, based on evidence from recent trials.  Stroke is a major contributor to the global cardiovascular disease burden (1). Major modifiable risk factors including elevated blood pressure, high...
  • 22 June 2020
    Reports from the 12th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Wouter Jukema  The post ODYSSEY OUTCOMES and stroke events appeared first on PCSK9 Forum.

Pages